Oculac (Povidone K25)

Povidone is a water‑soluble polymer that forms hydrogen bonds with ocular surface proteins, increasing viscosity and creating a protective film. This film retains moisture, reduces friction, and can bind and stabilize active pharmaceutical ingredients, enhancing their residence time on the eye.

The dosage of Oculac is determined by the prescribing clinician based on the specific indication and patient needs. Typical regimens involve one to two drops instilled into the affected eye(s) as often as required, but the exact frequency and duration must be individualized by a healthcare professional.

Safety data for povidone‑based ophthalmic solutions in pregnancy and lactation are limited. Because it is minimally absorbed systemically, it is generally considered low risk, but use should only occur when the potential benefit justifies any possible risk, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with traditional artificial tears, Oculac’s povidone base offers higher viscosity and better film‑forming properties, which can prolong ocular surface coverage. It also serves as a stabilizer for co‑formulated active agents, whereas many simple saline‑based drops lack this dual function. Choice depends on clinical need and physician preference.

Oculac should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the solution from direct sunlight, excessive heat and moisture. Once opened, use within the period indicated on the label and discard any remaining product after the recommended after‑opening date.

Oculac is applied topically to the eye as a sterile drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to create a pocket, and place the prescribed number of drops into the conjunctival sac. Avoid touching the dropper tip to any surface to maintain sterility.

Although rare, serious adverse reactions can include severe ocular inflammation, allergic hypersensitivity leading to swelling or ulceration, and vision‑impairing events. Patients should seek immediate medical attention if they experience intense redness, pain, loss of vision, or signs of an allergic reaction after using Oculac.

Individuals with a known hypersensitivity to povidone or any component of the formulation should avoid Oculac. It is also contraindicated in eyes with active infection unless directed by a specialist, and patients wearing contact lenses should remove lenses before instillation unless the product label specifically permits concurrent use.